205 related articles for article (PubMed ID: 29419469)
1. Risk Factors for Relapse of Antineutrophil Cytoplasmic Antibody-associated Vasculitis in Japan: A Nationwide, Prospective Cohort Study.
Hara A; Wada T; Sada KE; Amano K; Dobashi H; Harigai M; Takasaki Y; Yamada H; Hasegawa H; Hayashi T; Fujimoto S; Muso E; Kawakami T; Homma S; Yoshida M; Hirahashi J; Ogawa N; Ito S; Makino H; Arimura Y;
J Rheumatol; 2018 Apr; 45(4):521-528. PubMed ID: 29419469
[TBL] [Abstract][Full Text] [Related]
2. Predictors of damage accrual in patients with antineutrophil cytoplasmic antibody-associated vasculitis: A nationwide prospective study.
Hara A; Sada KE; Wada T; Amano K; Dobashi H; Atsumi T; Sugihara T; Hirayama K; Banno S; Murakawa Y; Hasegawa M; Yamagata K; Arimura Y; Makino H; Harigai M
Mod Rheumatol; 2024 Feb; 34(2):382-390. PubMed ID: 36988333
[TBL] [Abstract][Full Text] [Related]
3. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.
Karras A; Pagnoux C; Haubitz M; Groot K; Puechal X; Tervaert JWC; Segelmark M; Guillevin L; Jayne D;
Ann Rheum Dis; 2017 Oct; 76(10):1662-1668. PubMed ID: 28546260
[TBL] [Abstract][Full Text] [Related]
4. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics of and risk factors for serious infection in Japanese patients within six months of remission induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis registered in a nationwide, prospective, inception cohort study.
Watanabe-Imai K; Harigai M; Sada KE; Yamamura M; Fujii T; Dobashi H; Amano K; Ito S; Homma S; Kumagai S; Banno S; Arimura Y; Makino H;
Mod Rheumatol; 2017 Jul; 27(4):646-651. PubMed ID: 27538706
[TBL] [Abstract][Full Text] [Related]
7. Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial.
Furuta S; Sugiyama T; Umibe T; Kaneko Y; Amano K; Kurasawa K; Nakagomi D; Hiraguri M; Hanaoka H; Sato Y; Ikeda K; Nakajima H;
BMJ Open; 2017 Dec; 7(12):e018748. PubMed ID: 29247107
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Microscopic Hematuria after Induction of Remission in Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis.
Vandenbussche C; Bitton L; Bataille P; Glowacki F; Azar R; Hatron PY; Macnamara E; Gheerbrant JD; Cardon G; Hoffmann M; Auxenfants E; Gnemmi V; Quéméneur T
Am J Nephrol; 2019; 49(6):479-486. PubMed ID: 31117066
[TBL] [Abstract][Full Text] [Related]
9. Rationale of concomitant cyclophosphamide for remission-induction in patients with antineutrophil cytoplasmic antibody-associated vasculitis: A propensity score-matched analysis of two nationwide prospective cohort studies.
Watanabe H; Sada KE; Matsumoto Y; Harigai M; Amano K; Fujimoto S; Dobashi H; Yuzawa Y; Yamagata K; Muso E; Arimura Y; Makino H
Mod Rheumatol; 2021 Jan; 31(1):205-213. PubMed ID: 31859544
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of tissue inhibitor of metalloproteinase 1 as a predictor of sustained remission in patients with antineutrophil cytoplasmic antibody-associated vasculitis.
Ishizaki J; Takemori A; Horie K; Hiraoka D; Suemori K; Matsumoto T; Sada KE; Amano K; Harigai M; Arimura Y; Makino H; Takenaka K; Takemori N; Hasegawa H;
Arthritis Res Ther; 2021 Mar; 23(1):91. PubMed ID: 33743769
[TBL] [Abstract][Full Text] [Related]
11. Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study.
Sada KE; Yamamura M; Harigai M; Fujii T; Takasaki Y; Amano K; Fujimoto S; Muso E; Murakawa Y; Arimura Y; Makino H;
Arthritis Res Ther; 2015 Nov; 17():305. PubMed ID: 26525413
[TBL] [Abstract][Full Text] [Related]
12. Association Between Reappearance of Myeloperoxidase-Antineutrophil Cytoplasmic Antibody and Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Subgroup Analysis of Nationwide Prospective Cohort Studies.
Watanabe H; Sada KE; Matsumoto Y; Harigai M; Amano K; Dobashi H; Fujimoto S; Usui J; Yamagata K; Atsumi T; Banno S; Sugihara T; Arimura Y; Matsuo S; Makino H;
Arthritis Rheumatol; 2018 Oct; 70(10):1626-1633. PubMed ID: 29790303
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR
Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054
[TBL] [Abstract][Full Text] [Related]
14. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
Smith RM; Jones RB; Guerry MJ; Laurino S; Catapano F; Chaudhry A; Smith KG; Jayne DR
Arthritis Rheum; 2012 Nov; 64(11):3760-9. PubMed ID: 22729997
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial.
Maritati F; Alberici F; Oliva E; Urban ML; Palmisano A; Santarsia F; Andrulli S; Pavone L; Pesci A; Grasselli C; Santi R; Tumiati B; Manenti L; Buzio C; Vaglio A
PLoS One; 2017; 12(10):e0185880. PubMed ID: 29016646
[TBL] [Abstract][Full Text] [Related]
16. Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse.
Morgan MD; Szeto M; Walsh M; Jayne D; Westman K; Rasmussen N; Hiemstra TF; Flossmann O; Berden A; Höglund P; Harper L;
Arthritis Res Ther; 2017 Jun; 19(1):129. PubMed ID: 28592297
[TBL] [Abstract][Full Text] [Related]
17. Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial.
Gopaluni S; Smith RM; Lewin M; McAlear CA; Mynard K; Jones RB; Specks U; Merkel PA; Jayne DR;
Trials; 2017 Mar; 18(1):112. PubMed ID: 28270229
[TBL] [Abstract][Full Text] [Related]
18. Effect of Disease Activity at Three and Six Months After Diagnosis on Long-Term Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Gopaluni S; Flossmann O; Little MA; O'Hara P; Bekker P; Jayne D;
Arthritis Rheumatol; 2019 May; 71(5):784-791. PubMed ID: 30418705
[TBL] [Abstract][Full Text] [Related]
19. Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.
McGregor JG; Hogan SL; Kotzen ES; Poulton CJ; Hu Y; Negrete-Lopez R; Kidd JM; Katsanos SL; Bunch DO; Nachman PH; Falk RJ
Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1(Suppl 1):i123-31. PubMed ID: 25805743
[TBL] [Abstract][Full Text] [Related]
20. Increase of Antimyeloperoxidase Antineutrophil Cytoplasmic Antibody (ANCA) in Patients with Renal ANCA-associated Vasculitis: Association with Risk to Relapse.
Yamaguchi M; Ando M; Kato S; Katsuno T; Kato N; Kosugi T; Sato W; Tsuboi N; Yasuda Y; Mizuno M; Ito Y; Matsuo S; Maruyama S
J Rheumatol; 2015 Oct; 42(10):1853-60. PubMed ID: 26373560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
